Ⓐ
PeptiBrief
Peptide · Investigational biologic

ACE-083

Research peptide
Aliases · ACE083

An investigational locally acting muscle-growth agent that increased treated-muscle volume in clinical trials but did not consistently improve strength or function.

Human
2/5
Animal
0/5
In-vitro
0/5
Safety
2/5
Last reviewed · 7/11/2026
Compare with another peptide →
Last reviewed7/11/2026
Evidence statusEarly entry
Published references0
Trust signal panel
Evidence & safety
  • Human evidence
    n/a
  • Animal evidence
    n/a
  • Mechanistic
    n/a
  • Safety knowledge
    n/a
  • Editorial confidence
    4/5
View in knowledge graph →See this peptide connected to conditions & mechanisms
01

Evidence Snapshot

Evidence snapshot · 1 verified ref
Overall
2/5Emerging / preliminary
Human
2/5Some human clinical evidence
Animal
0/5None identified
In-vitro
0/5None identified
Safety
2/5Partially characterised safety
02

Scientific identity

Peptide family
Locally acting follistatin-based ligand trap
Entity class
Investigational biologic
Alternative names
ACE083
Discovery history

Developed by Acceleron Pharma as a locally acting modified follistatin fusion protein intended to inhibit myostatin and related activin-family ligands in injected muscle.

02

Proposed Mechanisms

03

Reported / Studied Uses

04

Human Evidence

Randomized phase 2 evidence in facioscapulohumeral muscular dystrophy showed significant increases in muscle volume without consistent functional or patient-reported benefit.

05

Animal Evidence

Preclinical studies supported local muscle hypertrophy and provided the rationale for human trials.

Species translation to humans is uncertain.
06

Safety & Unknowns

investigationalnot-licensedinjection-site-reactionsmuscle-size-without-function
Injection-site reactions were common. Increasing muscle volume without reliable functional improvement limits clinical relevance. Safety outside controlled trials and product quality in unregulated markets are uncertain.
07

Regulatory Status

CountryStatusNotes
08

Community Observations

No approved community reports yet. Submit one. Aggregate data is observational only.
09

References

  • No verified references linked yet. Editors will add primary sources.
10

Full Disclaimer

This page is for educational information only. It does not constitute medical advice, diagnosis, treatment, dosing guidance, or a recommendation to use any peptide, medicine or research chemical. Many peptides discussed on Atlas are not approved for human use in most jurisdictions and may have limited or unknown long-term safety data.

Community observations shown on this page are anonymised, moderated and observational only. They do not establish safety or effectiveness.

Always consult a qualified healthcare professional before making decisions about your health. See medical disclaimer and methodology.

↳

Explore further

from the knowledge graph
Conditions
Advertise here — support independent evidence →
ImportantPeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.